MedPath
Found 121 clinical trials|View Analysis
Sort by:

Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL

Phase 1
Not yet recruiting
Conditions
Diffuse Large B-Cell Lymphoma
Interventions
Drug: R-CMOP Regimen
Drug: R-CHOP Regimen
First Posted Date
2025-01-06
Last Posted Date
2025-01-06
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
112
Registration Number
NCT06760039
Locations
🇨🇳

Fujian Provincial Cancer Hospital, Fuzhou, Fujian, China

🇨🇳

Gansu Provincial Cancer Hospital, Lanzhou, Gansu, China

🇨🇳

The Fifth Affiliated Hospital of Guangzhou Medical University., Guangzhou, Guangdong, China

and more 7 locations

Surgery Alone Verus Sugery Combined with Dose-reduced Radiotherapy for Newly Diagnosed Stage I Nasopharyngeal Carcinoma

Not Applicable
Recruiting
Conditions
Nasopharyngeal Carcinoma
Surgery
Radiotherapy
First Posted Date
2024-11-14
Last Posted Date
2024-11-14
Lead Sponsor
Ming-Yuan Chen
Target Recruit Count
86
Registration Number
NCT06688760
Locations
🇨🇳

The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

🇨🇳

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Phase 3
Recruiting
Conditions
Nasopharyngeal Carcinoma
De-escalation Therapy
Interventions
Drug: Full course of PD-1/PD-L1 blockades
Drug: Cisplatin-based induction chemotherapy
Radiation: Standard-dose IMRT
Radiation: Gradient Fractionated IMRT
Drug: Concurrent Chemotherapy
First Posted Date
2024-11-05
Last Posted Date
2024-11-05
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
586
Registration Number
NCT06675214
Locations
🇨🇳

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

Irinotecan Liposome Combined with S-1 in PD-1/L1 Inhibitor Refractory Recurrent or Metastatic NPC

Phase 2
Recruiting
Conditions
Recurrent or Metastatic Nasopharyngeal Carcinoma
Interventions
First Posted Date
2024-10-24
Last Posted Date
2025-01-10
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
56
Registration Number
NCT06657690
Locations
🇨🇳

Fifth affiliated hosptial of Sun-yat Sen university, Zhuhai, Guangzhou, China

Innovating Shorter, All- Oral, Precised Treatment Regimen for Rifampicin Resistant Tuberculosis:BDLL Chinese Cohort

Phase 3
Not yet recruiting
Conditions
Drug-resistant Tuberculosis
Pulmonary Tuberculosis
Rifampin-resistant Tuberculosis
Interventions
First Posted Date
2024-10-21
Last Posted Date
2024-11-11
Lead Sponsor
Huashan Hospital
Target Recruit Count
120
Registration Number
NCT06649721
Locations
🇨🇳

Anhui Chest Hospital, Hefei, Anhui, China

🇨🇳

Beijing Tsinghua Changgun Hospital, Beijing, Beijing, China

🇨🇳

The 8th Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China

and more 36 locations

Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients(Rocket Trial)

Phase 2
Recruiting
Conditions
Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
Drug: Orelabrutinib Oral Tablet
Drug: R-CHOP Protocol
First Posted Date
2024-10-18
Last Posted Date
2024-10-22
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
39
Registration Number
NCT06647940
Locations
🇨🇳

Gansu Cancer Hospital, Lanzhou, Gansu, China

🇨🇳

Dongguan People's Hospital, Dongguan, Guangdong, China

🇨🇳

Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China

and more 8 locations

Efficacy of Trastuzumab Deruxtecan in Metastatic Breast Cancer with Different HER2 Expression Patterns

Recruiting
Conditions
Metastatic Breast Cancer
Interventions
First Posted Date
2024-08-13
Last Posted Date
2024-12-04
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
800
Registration Number
NCT06551220
Locations
🇨🇳

Fujian Cancer Hospital, Fujian Medical University, Fuzhou, Fujian, China

🇨🇳

The 10th Affiliated Hospital of Southern Medical University, Dongguan, Guangdong, China

🇨🇳

The First People's Hospital of Foshan, Foshan, Guangdong, China

and more 20 locations

Endoscopic Surgery vs. Intensity Modulated Radiotherapy for Stage I Nasopharyngeal Carcinoma.

Not Applicable
Recruiting
Conditions
Nasopharyngeal Carcinoma
Surgery
Intensity Modulated Radiotherapy
Interventions
Procedure: Endoscopic nasopharyngectomy followed close follow-up
Radiation: Intensity-modulated Radiotherapy
First Posted Date
2024-08-01
Last Posted Date
2024-08-01
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
442
Registration Number
NCT06533267
Locations
🇨🇳

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

Multimodality US Based on Angio Planewave Ultrasensitive Imaging and Shear Wave Elastography to Evaluate the Malignancy Risk Value of Thyroid Nodules

Recruiting
Conditions
Microvascular Classification
Multimoda Lultasound
Thyroid Cancer
Interventions
Diagnostic Test: ultrasound
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Fifth Affiliated Hospital, Sun Yat-Sen University
Target Recruit Count
720
Registration Number
NCT06530771
Locations
🇨🇳

The Fifth Affiliated Hospital Sun Yat-Sen University, Zhuhai, Guangdong, China

Surgery Plus Reduced Target Chemoradiotherapy vs Surgery Plus Reduced Dose Chemoradiotherapy for Newly Diagnosed Operable Nasopharyngeal Carcinoma.

Not Applicable
Recruiting
Conditions
Nasopharyngeal Carcinoma
Interventions
Radiation: Surgery combined with Dose-reduction intensity-modulated radiotherapy
Radiation: Surgery combined with Target-reduction intensity-modulated radiotherapy
First Posted Date
2024-07-31
Last Posted Date
2024-07-31
Lead Sponsor
Ming-Yuan Chen
Target Recruit Count
384
Registration Number
NCT06529562
Locations
🇨🇳

The Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, Guangdong, China

© Copyright 2025. All Rights Reserved by MedPath